Peripheral Arterial Disease Pad clinical trials

Explore recruiting peripheral arterial disease pad clinical trials.

Recruiting peripheral arterial disease pad studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Peripheral Arterial Disease Pad trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A contrast medium sparing strategy using automated Carbon Dioxide Injection during PERIpheral vascular interventions for PREVENTion of Major Adverse Kidney Events (MAKE): the PeriPREVENT randomized controlled trial

Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1/2, Open label & double-blind randomized placebo-controlled study to assess the feasibility of BGC101 (EnEPC) in the treatment of peripheral arterial disease (PAD) with critical limb ischemia (CLI)

Belgium

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase IIa Open Label, Dose-Finding, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients with Peripheral Arterial Disease (PAD). CLAUDIA Trial

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, FIRST-IN-HUMAN, PHASE 1B/2A STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE-DOSE TRI-001 IN PATIENTS WITH CHRONIC LIMB THREATENING ISCHEMIA (CLTI) DUE TO PERIPHERAL ARTERIAL DISEASE (PAD)

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Peripheral Arterial Disease Pad trials by city

Peripheral Arterial Disease Pad in Toronto Peripheral Arterial Disease Pad in Vancouver Peripheral Arterial Disease Pad in Montreal Peripheral Arterial Disease Pad in Calgary Peripheral Arterial Disease Pad in Edmonton Peripheral Arterial Disease Pad in Ottawa Peripheral Arterial Disease Pad in Winnipeg Peripheral Arterial Disease Pad in Quebec City Peripheral Arterial Disease Pad in Hamilton Peripheral Arterial Disease Pad in Kitchener Peripheral Arterial Disease Pad in London Peripheral Arterial Disease Pad in Halifax Peripheral Arterial Disease Pad in New York Peripheral Arterial Disease Pad in Los Angeles Peripheral Arterial Disease Pad in Chicago Peripheral Arterial Disease Pad in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease